Topical Ranibizumab as a Treatment of Corneal Neovascularization

Purpose: To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV). Methods: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA. Results: Statistically significant decreases in neovascular area (55.3%, P < 0.001), which lasted through 16 weeks, and VC (59%, P < 0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted. Conclusions: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.

[1]  H. Dua,et al.  Fine needle diathermy occlusion of corneal vessels , 2014, British Journal of Ophthalmology.

[2]  A. V. Ozeç,et al.  Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model. , 2012, International journal of ophthalmology.

[3]  P. Finger,et al.  Refractory Squamous Cell Carcinoma of the Conjunctiva Treated With Subconjunctival Ranibizumab (Lucentis): A Two-Year Study , 2012, Ophthalmic plastic and reconstructive surgery.

[4]  R. Dana,et al.  Corneal penetration of topical and subconjunctival bevacizumab. , 2011, Investigative ophthalmology & visual science.

[5]  Y. Çağlar,et al.  The Impact of Subconjuctivally Injected EGF and VEGF Inhibitors on Experimental Corneal Neovascularization in Rat Model , 2011, Current eye research.

[6]  I. Tsinopoulos,et al.  The Effect of Subconjunctival Ranibizumab on Primary Pterygium: A Pilot Study , 2010, Cornea.

[7]  K. Yoon,et al.  Recurrent Herpes Simplex Keratitis After Verteporfin Photodynamic Therapy for Corneal Neovascularization , 2010, Cornea.

[8]  U. Schmidt-Erfurth.  Clinical safety of ranibizumab in age-related macular degeneration , 2010, Expert opinion on drug safety.

[9]  O. Genevois,et al.  [Subconjunctival bevacizumab for corneal neovascularization]. , 2010, Journal francais d'ophtalmologie.

[10]  Kyungji Min,et al.  Bevacizumab application delays epithelial healing in rabbit cornea. , 2009, Investigative ophthalmology & visual science.

[11]  A. Mansour,et al.  Treatment of inflamed pterygia or residual pterygial bed , 2009, British Journal of Ophthalmology.

[12]  P. Finger,et al.  Subconjunctival ranibizumab for squamous cell carcinoma of the conjunctiva with corneal extension , 2009, British Journal of Ophthalmology.

[13]  Claus Cursiefen,et al.  Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin®) eye drops against corneal neovascularization , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[14]  M. Barakat,et al.  VEGF inhibitors for the treatment of neovascular age-related macular degeneration , 2009, Expert opinion on investigational drugs.

[15]  R. Dana,et al.  Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. , 2009, Archives of ophthalmology.

[16]  P. Kaiser,et al.  VEGF inhibitors for the treatment of neovascular age-related macular degeneration. , 2009, Expert opinion on investigational drugs.

[17]  D. Pieramici,et al.  Anti-VEGF therapy: comparison of current and future agents , 2008, Eye.

[18]  Min Zhang,et al.  Vascular endothelial growth factor mediates corneal nerve repair. , 2008, Investigative ophthalmology & visual science.

[19]  H. Tchah,et al.  The effect of topical bevacizumab on corneal neovascularization. , 2008, Ophthalmology.

[20]  F. Bremer.  [Origin of corticosteroid glaucoma]. , 2007, Bulletin de la Societe belge d'ophtalmologie.

[21]  R. Avery,et al.  Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. , 2006, Ophthalmology.

[22]  S. Aisenbrey.  Intravitreal Bevacizumab (AvastinTM) for Neovascular Age–Related Macular Degeneration (AMD) , 2006 .

[23]  J. P. Sy,et al.  Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. , 2006, Ophthalmology.

[24]  R. Avery,et al.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[25]  J. Sheppard,et al.  Argon laser photodynamic therapy of human corneal neovascularization after intravenous administration of dihematoporphyrin ether. , 2006, American journal of ophthalmology.

[26]  J. Slakter,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSION: A Short-Term Study , 2006, Retina.

[27]  D. Azar.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). , 2006, Transactions of the American Ophthalmological Society.

[28]  K. Maruyama,et al.  Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. , 2004, Investigative ophthalmology & visual science.

[29]  B. Ambati,et al.  Photodynamic therapy for corneal neovascularisation and lipid degeneration , 2004, British Journal of Ophthalmology.

[30]  D. Azar,et al.  Corneal neovascularization. , 2001, Current opinion in ophthalmology.

[31]  C. Humpel,et al.  Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. , 2000, Investigative ophthalmology & visual science.

[32]  W. Snyder,et al.  Photodynamic therapy for corneal neovascularization. , 1998, Ophthalmic surgery and lasers.

[33]  M. Dana,et al.  Loss and restoration of immune privilege in eyes with corneal neovascularization. , 1996, Investigative ophthalmology & visual science.

[34]  R. D. Stulting,et al.  Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. , 1994, Ophthalmology.

[35]  W. Charman,et al.  Role of lasers in eye care. , 1993, Optometry and vision science : official publication of the American Academy of Optometry.